OncoTherad

OncoTherad is a **nanostructured inorganic phosphate complex associated with a glycosidic protein** developed at the University of Campinas, Brazil, as a novel immunotherapy particularly for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG)[1][3][6]. It is a **nanoimmunotherapy** designed to activate the innate immune system predominantly through **Toll-like receptor 4 (TLR4)**, leading to enhanced interferon signaling and potent activation of cytotoxic CD8+ T cells, decreased immune checkpoints (notably PD-1/PD-L1), and reversal of immunosuppression in the bladder tumor microenvironment[3][4][5][6]. OncoTherad has demonstrated significant efficacy and safety in early-phase clinical trials for BCG-unresponsive NMIBC, with substantial rates of complete pathological response and recurrence-free survival, and is notable for its immune-mediated antitumor effect through multiple mechanisms[3][4][5].

Brand names

OncoTherad

Other names

nanostructured complex CFI-1MRB-CFI-1MRB-CFI1MRB-CFI 1